SCHEDULE 13G: Alafi Capital Discloses 9.6% Passive Stake in CalciMedica, Inc.

Alafi Capital Company, LLC and Christopher D. Alafi have jointly disclosed a 9.6% beneficial ownership stake in CalciMedica, Inc., totaling 1,295,678 shares of common stock, as reported in a recent Schedule 13G filing.

Summary

• Alafi Capital Company, LLC and Christopher D. Alafi (the "Reporting Persons") have filed a Schedule 13G, disclosing their beneficial ownership in CalciMedica, Inc.
• The Reporting Persons collectively beneficially own 1,295,678 shares of CalciMedica, Inc.'s common stock.
• This ownership represents 9.6% of the outstanding common stock of CalciMedica, Inc.
• The percentage is calculated based on 13,481,917 outstanding shares of common stock as of March 21, 2025, as reported in CalciMedica's Annual Report on Form 10-K filed on March 27, 2025.
• Christopher D. Alafi is the managing member of Alafi Capital Company, LLC and is deemed to have sole voting and dispositive power over the shares held by the LLC.
• The filing indicates that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, signifying a passive investment.

Sentiment

Score: 7

Explanation: The filing indicates a significant passive investment by Alafi Capital Company, LLC and Christopher D. Alafi in CalciMedica, Inc., suggesting investor confidence in the company's value. This is generally a positive signal, though it does not provide operational or financial performance updates from the company itself.

Positives

• A significant investor, Alafi Capital Company, LLC, and its managing member, Christopher D. Alafi, have taken a substantial 9.6% stake in CalciMedica, Inc., indicating confidence in the company's prospects and valuation.
• The filing as a Schedule 13G signifies a passive investment, suggesting the investor is not seeking to influence or change control of the company, which can be viewed as a stable, long-term commitment.

Future Outlook

NA

Industry Context

This Schedule 13G filing is a standard disclosure of a significant passive ownership stake by an institutional investor in a publicly traded company. It does not provide specific insights into broader industry trends but rather reflects an investor's confidence in a particular company within its sector.

Stakeholder Impact

• Shareholders: The disclosure of a significant passive stake by an institutional investor may be viewed positively, signaling investor confidence and potentially contributing to market stability for the stock.

Next Steps

• The Reporting Persons have agreed to jointly file any future statements on Schedule 13D or 13G (and any amendments or supplements thereto) required under Section 13(d) of the Securities Exchange Act of 1934, as amended, in connection with their purchases and sales of CalciMedica, Inc. securities.

Key Dates

Keywords

CalciMedica, Alafi Capital Company, Christopher D. Alafi, Schedule 13G, beneficial ownership, common stock, passive investment, SEC filing, institutional investor